Key facts
- This page summarizes Mark D. Plinio's Form 4 filing for Evelo Biosciences, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2023, 15:10.
Mark D. Plinio - 31 Jan 2023 Form 4 Insider Report for Evelo Biosciences, Inc.
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 31 Jan 2023
- Net transaction value
- +$1,100
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2023, 15:10:11 UTC
- Prior SEC filing
- 14 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dominic V. Capasso, Attorney-in-Fact for Mark Plinio
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark D. Plinio filed Form 4 for Evelo Biosciences, Inc. on 02 Feb 2023.
Change
- Previous filing in this sequence was filed on 14 Oct 2022.
- Current net transaction value: +$1,100.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVLO
transaction
Common Stock
Award
- Transaction value
- $1,100
- Shares
- +1,250
- Change %
- +50%
- Price
- $0.8800
- Shares after
- 3,750
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Evelo Biosciences, Inc. 2018 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of August 1, 2022 through January 31, 2023. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
Footnote F2
The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of January 31, 2023.
Footnote F3
In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of common stock on the Purchase Date of January 31, 2023.